Ashish Bansal
About
Ashish Bansal is a scholar working on Dermatology, Physiology and Immunology and Allergy.
According to data from OpenAlex, Ashish Bansal has authored 84 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Dermatology, 43 papers in Physiology and 40 papers in Immunology and Allergy. Recurrent topics in Ashish Bansal's work include Dermatology and Skin Diseases (61 papers), Asthma and respiratory diseases (43 papers) and Allergic Rhinitis and Sensitization (32 papers). Ashish Bansal is often cited by papers focused on Dermatology and Skin Diseases (61 papers), Asthma and respiratory diseases (43 papers) and Allergic Rhinitis and Sensitization (32 papers). Ashish Bansal collaborates with scholars based in United States, Germany and United Kingdom. Ashish Bansal's co-authors include Eric L. Simpson, Naimish Patel, Amy S. Paller, Ana B. Rossi, Michael J. Cork, Bolanle Akinlade, Elaine C. Siegfried, Neil M.H. Graham, Laurent Eckert and Mohamed Kamal and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and SHILAP Revista de lepidopterología.
In The Last Decade
Ashish Bansal
72 papers receiving 1.0k citations
Hit Papers
Peers
Ashish Bansal
Albert F. Finn United States
Rémi Gagnon Canada
Miguel Villarreal United States
A.M. Chiriac France
S. Hedgecock United Kingdom
Juby A. Jacob‐Nara United States
Paul J. Rowe United States
Lindsy Frazer-Green United States
Noriko Seko Japan
Kyu‐Earn Kim South Korea
Citations per year, relative to Ashish Bansal Ashish Bansal (= 1×)
peers
Albert F. Finn
Countries citing papers authored by Ashish Bansal
Since
Specialization
Citations
This map shows the geographic impact of Ashish Bansal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashish Bansal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashish Bansal more than expected).
Fields of papers citing papers by Ashish Bansal
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ashish Bansal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashish Bansal. The network helps show where Ashish Bansal may publish in the future.
Co-authorship network of co-authors of Ashish Bansal
This figure shows the co-authorship network connecting the top 25 collaborators of Ashish Bansal. A scholar is included among the top collaborators of Ashish Bansal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashish Bansal. Ashish Bansal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Christenson, Stephanie A., Nicola A. Hanania, Surya P. Bhatt, et al.. (2025). Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. 13(8). 687–697.
2.
Bhatt, Surya P., Klaus F. Rabe, Nicola A. Hanania, et al.. (2025). Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS. CHEST Journal. 168(1). 56–66.
3.
Langley, Richard G., Anna Coleman, Marius Ardeleanu, et al.. (2025). The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults. American Journal of Clinical Dermatology. 26(6). 981–1002.
4.
Bafadhel, Mona, Stephanie A. Christenson, Claus Vogelmeier, et al.. (2024). IN PATIENTS WITH MODERATE OR SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION, DUPILUMAB DOES NOT IMPACT BLOOD EOSINOPHIL LEVELS: PHASE 3 BOREAS TRIAL. CHEST Journal. 166(4). A4831–A4834.
5.
Papi, Alberto, Nicola A. Hanania, Surya P. Bhatt, et al.. (2024). Dupilumab Improves Pre-bronchodilator Lung Function Measures in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the Phase 3 Boreas Trial. A1199–A1199.
6.
Siegfried, Elaine C., Lara Wine Lee, Jonathan M. Spergel, et al.. (2024). A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis. Pediatric Dermatology. 41(2). 204–209.
7.
Christenson, Stephanie A., Nicola A. Hanania, Surya P. Bhatt, et al.. (2024). In the Phase 3 Boreas Trial, Baseline Blood Eosinophils and Baseline Fractional Exhaled Nitric Oxide Levels Predict the Response to Dupilumab in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease and Type 2 Inflammation. A6620–A6620.
8.
Vogelmeier, Claus, Mona Bafadhel, Stephanie A. Christenson, et al.. (2024). DUPILUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: THE PHASE 3 NOTUS TRIAL. CHEST Journal. 166(4). A4814–A4818.
9.
Vogelmeier, Claus, Mona Bafadhel, Stephanie A. Christenson, et al.. (2024). DUPILUMAB REDUCES EXACERBATIONS AND IMPROVES LUNG FUNCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND EMPHYSEMA. CHEST Journal. 166(4). A4809–A4813.
10.
Bhatt, Surya P., Klaus F. Rabe, Nicola A. Hanania, et al.. (2024). Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). Respiratory Medicine. 236. 107846–107846.
11.
Kwatra, Shawn G., Gil Yosipovitch, Sonja Ständer, et al.. (2023). 42275 Dupilumab Improves Itch, Skin Pain, and Sleep in Adult Patients With Prurigo Nodularis (LIBERTY PN-PRIME and PRIME2). Journal of the American Academy of Dermatology. 89(3). AB40–AB40.
12.
Ständer, Sonja, et al.. (2023). 42895 Validation of the skin pain numeric rating scale (NRS) in prurigo nodularis (PN) based on clinical studies of dupilumab in adults with PN. Journal of the American Academy of Dermatology. 89(3). AB103–AB103.
13.
Simpson, Eric L., Jonathan I. Silverberg, Margitta Worm, et al.. (2023). 106 Dupilumab treatment in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Journal of Investigative Dermatology. 143(11). S350–S350.
14.
Briggs, Emily, Mohamed Kamal, Matthew P. Kosloski, et al.. (2023). Integrated Exposure–Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis. Pharmaceutical Research. 40(11). 2653–2666.
15.
Weidinger, Stephan, Eric L. Simpson, Jonathan I. Silverberg, et al.. (2023). Efficacy of dupilumab in moderate and severe atopic dermatitis. SHILAP Revista de lepidopterología. 2(2). 247–260.
16.
Barbarot, S., Abhijit Gadkari, Eric L. Simpson, et al.. (2022). The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional Study. The Journal of Pediatrics. 246. 220–226.e5.
17.
Siegfried, Elaine C., Thomas Bieber, Eric L. Simpson, et al.. (2021). Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. American Journal of Clinical Dermatology. 22(2). 243–255.
18.
Paller, Amy S., Ashish Bansal, Eric L. Simpson, et al.. (2019). Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. American Journal of Clinical Dermatology. 21(1). 119–131.
19.
Cork, Michael J., Lawrence F. Eichenfield, Andrew Blauvelt, et al.. (2019). 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. Journal of Investigative Dermatology. 139(5). S104–S104.
20.
Bansal, Ashish, et al.. (2014). Evidence of vitamin D deficiency and its relation with possible cardiovascular risk among postmenopausal women.. 5(2). 41–45.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Albert F. Finn Breakdown of academic impact, for papers by Rémi Gagnon Breakdown of academic impact, for papers by Miguel Villarreal Breakdown of academic impact, for papers by A.M. Chiriac Breakdown of academic impact, for papers by S. Hedgecock Breakdown of academic impact, for papers by Juby A. Jacob‐Nara Breakdown of academic impact, for papers by Paul J. Rowe Breakdown of academic impact, for papers by Lindsy Frazer-Green Breakdown of academic impact, for papers by Noriko Seko Breakdown of academic impact, for papers by Kyu‐Earn Kim